Humacyte, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 25.11 million compared to USD 3.72 million a year ago. Basic loss per share from continuing operations was USD 0.24 compared to USD 0.04 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.48 USD | +16.60% | +20.70% | +92.96% |
10/05 | Transcript : Humacyte, Inc., Q1 2024 Earnings Call, May 10, 2024 | |
28/03 | Transcript : Humacyte, Inc. - Special Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+92.96% | 653M | |
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+42.44% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |
- Stock Market
- Equities
- HUMA Stock
- News Humacyte, Inc.
- Humacyte, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023